Venus Medtech Hangzhou Inc
HKEX:2500
Intrinsic Value
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. [ Read More ]
The intrinsic value of one
Venus Medtech Hangzhou Inc
stock under the Base Case scenario is
13.08
HKD.
Compared to the current market price of 5.62 HKD,
Venus Medtech Hangzhou Inc
is
Undervalued by 57%.
Venus Medtech Hangzhou Inc's market capitalization is 2.5B HKD.
Venus Medtech Hangzhou Inc stock price is 5.62 HKD.
Venus Medtech Hangzhou Inc stock price (5.62 HKD) is 57% less than its Intrinsic Value (13.08 HKD).
Venus Medtech Hangzhou Inc stock price (5.62 HKD) is 68% less than its DCF Value (17.8 HKD). Open DCF Valuation
Venus Medtech Hangzhou Inc stock price (5.62 HKD) is 33% less than its Relative Value (8.36 HKD). Open Relative Valuation
Venus Medtech Hangzhou Inc has upside potential of 83% compared to the average analyst price target.
Open Wall St Estimates
Venus Medtech Hangzhou Inc's Revenue has grown by an exceptional 21% over the past 12 months.
Venus Medtech Hangzhou Inc's Revenue is forecast to grow at a rate of 33% per year over the next 3 years.
Venus Medtech Hangzhou Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -19%.
Venus Medtech Hangzhou Inc has negative Operating Income for the last twelve months.
Venus Medtech Hangzhou Inc has negative Net Income for the last twelve months.
Venus Medtech Hangzhou Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -21%.
Venus Medtech Hangzhou Inc has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (651m CNY).
Venus Medtech Hangzhou Inc has positive Gross Profit for the last twelve months.
Venus Medtech Hangzhou Inc's long-term assets (5B CNY) exceed its long-term liabilties (2B CNY).
Venus Medtech Hangzhou Inc has negative Free Cash Flow for the last twelve months.
Venus Medtech Hangzhou Inc's short-term assets (2B CNY) exceed its short-term liabilties (633m CNY).
Venus Medtech Hangzhou Inc's D/E (Debt to Equity) is very low and is equal to 0.2.
Venus Medtech Hangzhou Inc has negative three-year average ROE (Return on Equity): -19%. The company is not efficient at transforming stockholders' equity into net income.
Venus Medtech Hangzhou Inc has negative three-year average ROIC (Return on Invested Capital): -26%. The company is not efficient at using invested capital to generate operating income.
Venus Medtech Hangzhou Inc's Altman Z-Score is very low and is equal to -0.06.
Venus Medtech Hangzhou Inc doesn't generate enough operating income (-677m CNY) to safely cover interest payments on its debt (55m CNY).
Valuation Backtest
Venus Medtech Hangzhou Inc
Run backtest to discover the historical profit from buying and selling
Venus Medtech Hangzhou Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Venus Medtech Hangzhou Inc
Balance Sheet Decomposition
Venus Medtech Hangzhou Inc
| Current Assets | 2.1B |
| Cash & Short-Term Investments | 1.5B |
| Receivables | 401.6m |
| Other Current Assets | 251.4m |
| Non-Current Assets | 2.9B |
| Long-Term Investments | 502.9m |
| PP&E | 495.7m |
| Intangibles | 1.9B |
| Other Non-Current Assets | 17.9m |
| Current Liabilities | 633.3m |
| Accounts Payable | 24.6m |
| Short-Term Debt | 129.8m |
| Other Current Liabilities | 478.9m |
| Non-Current Liabilities | 1.1B |
| Long-Term Debt | 521.1m |
| Other Non-Current Liabilities | 532.7m |
Earnings Waterfall
Venus Medtech Hangzhou Inc
|
Revenue
|
491.4m
CNY
|
|
Cost of Revenue
|
-102.2m
CNY
|
|
Gross Profit
|
389.2m
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
-677.4m
CNY
|
|
Other Expenses
|
-43.5m
CNY
|
|
Net Income
|
-720.9m
CNY
|
Free Cash Flow Analysis
Venus Medtech Hangzhou Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Venus Medtech Hangzhou Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Venus Medtech Hangzhou Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Venus Medtech Hangzhou Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Venus Medtech Hangzhou Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Venus Medtech Hangzhou Inc
According to Wall Street analysts, the average 1-year price target for
Venus Medtech Hangzhou Inc
is 10.28 HKD
with a low forecast of 5.05 HKD and a high forecast of 15.75 HKD.
Shareholder Return
Price
Venus Medtech Hangzhou Inc
| Average Annual Return | -4.19% |
| Standard Deviation of Annual Returns | 78.76% |
| Max Drawdown | -96% |
| Market Capitalization | 2.5B HKD |
| Shares Outstanding | 441 010 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Venus Medtech Hangzhou Inc
Country
Industry
Market Cap
Dividend Yield
Description
Venus Medtech (Hangzhou), Inc. provides transcatheter heart valve medical device. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2019-12-10. The firm's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.
Contact
IPO
Employees
Officers
The intrinsic value of one
Venus Medtech Hangzhou Inc
stock under the Base Case scenario is
13.08
HKD.
Compared to the current market price of 5.62 HKD,
Venus Medtech Hangzhou Inc
is
Undervalued by 57%.
You don't have any saved screeners yet
